In the very recent update, UDG Healthcare Plc said it projected a 5-8 percent ascend in adjusted full-year earnings per share on a constant-currency basis, and that reported EPS could be higher than this if exchange rates remained constant around current levels.
Shares in the FTSE-250 corporation, which presents outsourced sales and marketing, drug distribution and packaging services to healthcare companies, climbed more than 5 percent to a record high of 417.5 pence in morning trade on Tuesday.
Ultimate Gainer From Biotech Sector:
Hemispherx BioPharma, Inc(NYSEMKT:HEB), was the pre-market leader in healthcare sector, jumping 36.43% to settle at $0.300, following the news that a specialty pharmaceutical company, declared the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID).
Hemispherx BioPharma, Inc(NYSEMKT:HEB), a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
Other Positive movers for Monday’s trade are described as under:
Curis, Inc.(NASDAQ:CRIS), mounted 5.98% to close at $1.95, soon after an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, recently declared that the Company will present at the 2015 Bio CEO and Investor Conference at 2:30 p.m. ET on Tuesday, February 10, 2015, in New York City.
Curis, Inc.(NASDAQ:CRIS), is engaged in the research, development, and commercialization of cancer therapeutics.
Regado Biosciences Inc(NASDAQ:RGDO), escalated 5.69% in its last trade, following a biopharmaceutical company, and Tobira Therapeutics, Inc. declared that they have signed a definitive contract under which privately-held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases.
Regado Biosciences Inc(NASDAQ:RGDO), a biopharmaceutical company, focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.
Opko Health Inc.(NYSE:OPK), skyrocketed 4.12% to close at $12.63, after The corp. declared the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO’s long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
Opko Health Inc.(NYSE:OPK), a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics.
Galena Biopharma Inc (NASDAQ:GALE), mounted 3.07% to close at $1.68, soon after a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, declared that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 11:00 a.m. ET at The Waldorf Astoria Hotel in New York, NY.
Galena Biopharma Inc(NASDAQ:GALE), a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care.
